ProMIS Neurosciences Seeks Shareholder Nod for 1:5 to 1:25 Reverse Split

TL;DR

**PMN is pushing a reverse split to pump its stock price and stay listed – vote YES if you want institutional money, NO if you think it's a band-aid.**

AI Summary

ProMIS Neurosciences Inc. (PMN) is holding a Special Meeting on November 17, 2025, to seek shareholder approval for a share consolidation (reverse stock split) at a ratio ranging from one-for-five up to one-for-twenty-five, to be determined by the Board of Directors within one year. This strategic move aims to potentially increase the per-share trading price, which could help the company meet listing requirements of major exchanges and attract institutional investors. Shareholders as of the September 26, 2025 Record Date, owning 53,811,110 Common Shares, are eligible to vote. The Board recommends voting in favor of the share consolidation and a proposal to adjourn the meeting until December 17, 2025, if initial votes are insufficient. The meeting will be entirely virtual, accessible via www.virtualshareholdermeeting.com/PMN2025SM, emphasizing digital engagement for voting and questions.

Why It Matters

This proposed share consolidation is a critical move for ProMIS Neurosciences, potentially impacting its stock's liquidity and market perception. For investors, a higher per-share price could make the stock more attractive to institutional funds and help maintain or achieve listing on major exchanges, which often have minimum price requirements. This could improve the company's competitive standing against other biotech firms by enhancing its financial optics. Employees and customers might see this as a step towards greater financial stability and growth, signaling the company's commitment to long-term viability in the competitive neuroscience drug development sector.

Risk Assessment

Risk Level: medium — The share consolidation carries medium risk. While it aims to increase the per-share price, there's no guarantee it will sustain the price or attract new investors, as evidenced by the discretionary ratio from one-for-five up to one-for-twenty-five, indicating uncertainty. Furthermore, reverse stock splits can sometimes be perceived negatively by the market, potentially leading to further stock price declines post-consolidation.

Analyst Insight

Investors should vote in favor of Proposal No. 1 to support the company's efforts to improve its stock's marketability and exchange listing compliance. However, closely monitor the stock's performance post-consolidation, as reverse splits don't guarantee long-term value creation and can sometimes signal underlying operational challenges.

Key Numbers

• November 17, 2025 — Special Meeting Date (Date shareholders will vote on the share consolidation)
• September 26, 2025 — Record Date (Date by which shareholders must own shares to vote)
• 8:00 a.m., Eastern Time — Meeting Start Time (Time the virtual Special Meeting will commence)
• 1:5 to 1:25 — Share Consolidation Ratio Range (Discretionary range for the reverse stock split)
• 53,811,110 — Common Shares Outstanding (Number of shares eligible to vote as of the Record Date)
• October 3, 2025 — Notice Date (Date the Notice of Special Meeting was authorized)
• October 8, 2025 — Proxy Materials Availability Date (Date proxy materials were first made available to shareholders)
• December 17, 2025 — Adjournment Deadline (Latest date for an adjourned meeting if Proposal No. 2 is approved)

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant and issuer of common shares
• Neil K. Warma (person) — Chief Executive Officer of ProMIS Neurosciences Inc.
• Securities and Exchange Commission (regulator) — Regulates proxy statement filings
• Canadian Securities Administrators (regulator) — Regulates proxy statement filings under Canadian law
• Computershare Trust Company of Canada (company) — Transfer agent and registrar for ProMIS Neurosciences Inc.
• Computershare Trust Company, N.A. (company) — Transfer agent and registrar for ProMIS Neurosciences Inc.
• Nasdaq (company) — Stock exchange where NYSE rules for brokers apply
• New York Stock Exchange (company) — Stock exchange with rules for broker voting
• Ontario Business Corporations Act (regulator) — Governs corporate actions for ProMIS Neurosciences Inc.

FAQ

Industry Context

ProMIS Neurosciences operates in the biotechnology sector, focusing on developing therapies for neurodegenerative diseases. This sector is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Companies often seek to increase their share price to maintain stock exchange listings and attract the substantial capital required for clinical trials and commercialization.

Regulatory Implications

The proposed share consolidation is intended to help ProMIS Neurosciences meet the minimum bid price requirements for listing on major stock exchanges. Failure to maintain these listing requirements could lead to delisting, significantly impacting liquidity and investor confidence.

What Investors Should Do

1. Vote on Proposal 1 (Share Consolidation)
2. Vote on Proposal 2 (Adjournment)
3. Attend the Virtual Special Meeting

Key Dates

• 2025-11-17: Special Meeting of Shareholders — Shareholders will vote on the proposed share consolidation and potential adjournment.
• 2025-09-26: Record Date — Establishes the list of shareholders eligible to vote at the Special Meeting.
• 2025-10-03: Notice Date — Date the Notice of Special Meeting was authorized, indicating the start of the formal proxy solicitation process.
• 2025-10-08: Proxy Materials Availability Date — Date shareholders were first able to access proxy materials online, allowing time for review before the meeting.
• 2025-12-17: Adjournment Deadline — Latest possible date for an adjourned meeting if the initial share consolidation proposal does not pass, providing an opportunity to solicit more votes.

Glossary

Share Consolidation

A corporate action where a company reduces the number of its outstanding shares by combining them into a smaller number of shares, typically to increase the per-share price. (The primary purpose of the Special Meeting is to obtain shareholder approval for a share consolidation, which ProMIS Neurosciences believes will help meet exchange listing requirements and attract investors.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends, vote on corporate matters, or receive other distributions. (Shareholders who owned Common Shares as of September 26, 2025, are eligible to vote at the Special Meeting.)

Proxy Statement

A document required by the SEC that provides shareholders with information about matters to be voted on at a shareholder meeting, including details about proposals, board recommendations, and executive compensation. (This document outlines the proposals for the Special Meeting and provides shareholders with the necessary information to make informed voting decisions.)

Virtual Meeting

A shareholder meeting conducted entirely online, allowing participants to attend, vote, and ask questions remotely via the internet. (ProMIS Neurosciences is holding its Special Meeting virtually to facilitate broader participation and accessibility for its shareholders.)

Adjournment

The postponement of a meeting to a later date or time. (Shareholders are being asked to approve a proposal to adjourn the meeting if the primary proposal (share consolidation) does not receive sufficient votes, allowing more time to solicit proxies.)

Control Number

A unique identifier provided to shareholders, often found on proxy cards or email notifications, required for online registration and voting for virtual meetings. (Shareholders need their control number to register and participate in the virtual Special Meeting and to vote electronically.)

Year-Over-Year Comparison

This filing is a proxy statement for a special meeting focused on a share consolidation, rather than a comprehensive annual report. Therefore, direct year-over-year comparisons of financial metrics like revenue, net income, or margins are not available within this document. The primary focus is on the strategic decision to adjust the share structure to address potential listing requirements and market perception.

Filing Documents

• pmn-20251117xdef14a.htm (DEF 14A) — 280KB
• pmn-20251117xdef14a_a003.jpg (GRAPHIC) — 16KB
• pmn-20251117xdef14a_bg001.jpg (GRAPHIC) — 179KB
• pmn-20251117xdef14a_bg002.jpg (GRAPHIC) — 143KB
• pmn-20251117xdef14a_bg003.jpg (GRAPHIC) — 24KB
• pmn-20251117xdef14a_cg001.jpg (GRAPHIC) — 113KB
• pmn-20251117xdef14a_cg002.jpg (GRAPHIC) — 139KB
• 0001104659-25-096657.txt ( ) — 1114KB

From the Filing

DEF 14A 1 pmn-20251117xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 PROMIS NEUROSCIENCES INC. (Name of Registrant as Specified in its Charter) Not applicable. (Name of Person (s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25 (b) per Exchange Act Rules 14a-6 (i) (1) and 0-11. Table of Contents PROMIS NEUROSCIENCES INC. SUITE 200, 1920 YONGE STREET TORONTO, ONTARIO, CANADA M4S 3E2 (416) 847-6898 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS To Be Held on November 17, 2025 To Our Shareholders: You are cordially invited to attend a Special Meeting of shareholders ("Special Meeting") of ProMIS Neurosciences Inc. (the "Company"). This Special Meeting will be a virtual meeting, which will be conducted via live webcast on Monday, November 17, 2025 at 8:00 a.m., Eastern Time. You may attend the Special Meeting virtually by registering at www.virtualshareholdermeeting.com/PMN2025SM , where you will be able to vote electronically and submit questions, subject to the registration procedures set forth below. Only shareholders who owned common shares, no par value per share (the "Common Shares" or "shares") at the close of business on September 26, 2025 (the "Record Date") can vote at the Special Meeting or any adjournment that may take place. At the Special Meeting, the shareholders will consider and vote on the following matters: 1. to consider and, if deemed advisable, to pass a special resolution authorizing the filing of articles of amendment to effect a share consolidation of our Common Shares at a ratio ranging from one-for-five up to one-for-twenty-five, to be determined at the discretion of the Board of Directors (the "Board"), and effected, if at all, within one year from the date of the Special Meeting, with such effective date to be determined at the discretion of the Board and 2. In the event there are not sufficient votes in favor of the foregoing proposal and such proposal is not approved by shareholders, to approve the adjournment of the Special Meeting by the Chairperson to a date no later than December 17, 2025 at 8:00 a.m., Eastern Time, in accordance with the Company's Bylaws, to solicit additional proxies; provided, the Company shall provide updated instructions to attend such adjournment as necessary. As noted above, our Special Meeting will be a "virtual meeting" of shareholders, which will be conducted exclusively via the Internet. There will not be a physical meeting location, and shareholders will not be able to attend the Special Meeting in person. You may attend the Special Meeting via the Internet, vote your shares during the Special Meeting, and submit questions before the Special Meeting by registering at www.virtualshareholdermeeting.com/PMN2025SM . In order to attend the Special Meeting online, vote your shares electronically during the Special Meeting and submit questions before the meeting, registered shareholders must register in advance at www.virtualshareholdermeeting.com/PMN2025SM using the control number located in the box in the upper right-hand corner of your proxy card or in the body of the e-mail notification you received. Most of our shareholders do not hold shares directly in their own name but instead are non-registered shareholders who beneficially own shares that are held by an intermediary, such as their bank, trust company, securities broker, trustee, or other nominee. If you are a non-registered shareholder and wish to attend the Special Meeting online, vote your shares electronically during the meeting and submit questions before the Special Meeting, you must appoint yourself as your proxyholder following the procedures provided to you by your intermediary and register in advance at www.virtualshareholdermeeting.com/PMN2025SM . Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you to access the Special Meeting and will permit you to submit questions. Further information about how to attend the Special Meeting online, vote your shares and submit questions is included in the accompanying proxy statement. You can find more information in the proxy statement for the Special Meeting, which is attached and also available for viewing, printing and downloading at www.proxyvote.com . As outlined in the att